Uroporphyria in the uroporphyrinogen decarboxylase-deficient mouse: Interplay with siderosis and polychlorinated biphenyl exposure

Hepatology

Volumn 36, Issue 4 I, 2002, Pages 805-811

  Franklin, Michael R ^a   Phillips, John D ^a   Kushner, James P ^a  

^a Division of Hematology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLYCHLORINATED BIPHENYL; UROPORPHYRIN; UROPORPHYRINOGEN DECARBOXYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOSOL; DISEASE MODEL; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENETIC RISK; HEPATIC PORPHYRIA; HETEROZYGOSITY; HOMOZYGOSITY; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PORPHYRIA CUTANEA TARDA; PRIORITY JOURNAL; RISK FACTOR; SIDEROSIS;

ANIMALS; ANTITHYROID AGENTS; AROCLOR 1254; DISEASE MODELS, ANIMAL; FEMALE; GENOTYPE; HEMOCHROMATOSIS; IRON; IRON-DEXTRAN COMPLEX; LIVER; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; POLYCHLORINATED BIPHENYLS; PORPHYRIA CUTANEA TARDA; PORPHYRINS; SIDEROSIS; UROPORPHYRINOGEN DECARBOXYLASE;

EID: 0036787525     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0270-9139(02)00086-1     Document Type: Article

References (33)

1. Elder GH. Porphyria cutanea tarda. Semin Liver Dis 1998;18:67-75.
2. Bulaj ZJ, Phillips JD, Ajioka RS, Franklin MR, Griffen LM, Guinee DJ, Edwards CQ, et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 2000;95:1565-1571.
3. Bonkovsky HL, Poh-Fitzpatrick M, Pimstone N, Obando J, Di Bisceglie A, Tattrie C, Tortorelli K, et al. Porphyria cutanea tarda, hepatitis C, and HFE gene mutations in North America. Hepatology 1998;27:1661-1669.
4. Brady JJ, Jackson HA, Roberts AG, Morgan RR, Whatley SD, Rowlands GL, Darby C, et al. Co-inheritance of mutations in the uroporphyrinogen decarboxylase and hemochromatosis genes accelerates the onset of porphyria cutanea tarda. J Invest Dermatol 2000;115:868-874.
5. Schmid R. Cutaneous porphyria in Turkey. New Engl J Med 1960;263:397-398.
6. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The Porphyrias. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. Volume 2. New York: McGraw-Hill, 1995;2103-2160.
7. Rios de Molina MC, Wainstok de Calmanovici R, San Martin de Viale LC. Investigations on the presence of porphyrinogen carboxy-lyase inhibiror in the liver of rats intoxicated with hexachlorobenzene, Int. J Biochem 1980;12:1027-1032.
8. Cantoni L, dal Flume D, Rizzardini M, Ruggieri R. In vitro inhibitory effect on porphyrinogen carboxylyase of liver extracts from TCDD treated mice. Toxicol Lett 1984;20:211-217.
9. Smith AG, Francis JE. Chemically induced formation of an inhibitor of hepatic uroporphyrinogen decarboxylase in inbred mice with iron overload. Biochem J 1987;246:221-226.
10. Franklin MR, Phillips JD, Kushner JP. Accelerated development of uroporphyria in mice heterozygous at the uroporphyrinogen decarboxylase locus. J Biochem Mol Toxicol 2001;15:287-293.
11. Deam S, Elder GH. Uroporphyria produced in mice by iron and 5-aminolevulinic acid. Biochem Pharmacol 1991;41:2019-2022.
12. Constantin D, Francis JE, Akhtar RA, Clothier B, Smith AG. Uroporphyria induced by 5-aminolaevulinic acid alone in Ahrd SWR mice. Biochem Pharmacol 1996;52:1407-1413.
13. Gorman N, Walton HS, Bement WJ, Honsinger CP, Szakacs JG, Sinclair JF, Sinclair PR. Role of small differences in CYP1A2 in the development of uroporphyria produced by iron and 5-aminolevulinate in C57BL/6 and SWR strains of mice. Biochem Pharmacol 1999;58:375-382.
14. Phillips JD, Jackson LK, Bunting M, Franklin MR, Thomas KR, Levy JE, Andrews NC, et al. A mouse model of familial porphyria cutanea tarda. Proc Natl. Acad Sci U S A 2001;98:259-264.
15. Sinclair PR, Gorman N, Walton HS, Bement WJ, Sinclair JF, Gerhard GS, Szakacs JG, et al. Uroporphyria in Hfe mutant mice given 5-aminolevulinate: a new model of Fe-mediated porphyria cutanea tarda. Hepatology 2001;33:406-412.
16. Smith AG, Francis JE. Synergism of iron and hexachlorobenzene inhibits hepatic uroporphyrinogen decarboxylase in inbred mice. Biochem J 1983;214:909-913.
17. Urquhart AJ, Elder GH, Roberts AG, Lambrecht RW, Sinclair PR, Bement WJ, Gorman N, et al. Uroporphyria produced in mice by 20-methylcholanthrene and 5-aminolaevulinic acid. Biochem J 1988;253:337-362.
18. Sinclair PR, Bement WJ, Lambrecht RW, Jacobs JM, Sinclair JF. Uroporphyria caused by acetone and 5-aminolevulinic acid in iron-loaded mice. Biochem Pharmacol 1989;38:4341-4344.
19. Smith AG, Francis JE. Genetic variation of iron-induced uroporphyria in mice. Biochem J 1993;291:29-35.
20. Gorman N, Ross KL, Walton HS, Bement WJ, Szakacs JG, Gerhard GS, Dalton TP, et al. Uroporphyria in mice: thresholds for hepatic CYP1A2 and iron. Hepatology 2002;35::912-921.
21. Franklin MR, Phillips JD, Kushner JP. Cytochrome P450 induction, uroporphyrinogen decarboxylase depression, porphyrin accumulation and excretion, and gender influence in a 3-week rat model of porphyria cutanea tarda. Toxicol Appl Pharmacol 1997;147:289-299.
22. Smith AG, Francis JE, Green JA, Greig JB, Wolf CR, Manson MM. Sex-linked hepatic uroporphyria and the induction of cytochromes P450IA in rats caused by hexachlorobenzene and polyhalogenated biphenyls. Biochem Pharmacol 1990;40:2059-2068.
23. Mylchreest E, Charbonneau M. Studies on the mechanism of uroporphyrinogen decarboxylase inhibition in hexachlorobenzene-induced porphyria in the female rat. Toxicol Appl Pharmacol 1997;145:23-33.
24. Taljaard JJ, Shanley BC, Deppe WM, Joubert SM. Porphyrin metabolism in experimental hepatic siderosis in the rat. II. Combined effect of iron overload and hexachlorobenzene. Br J Haematol 1972;23:513-519.
25. Van Ommen B, Hendriks W, Bessems JG, Geesink G, Muller F, van Bladeren PJ. The relation between the oxidative biotransformarion of hexachlorobenzene and its porphyrinogenic activity. Toxicol Appl Pharmacol 1989;100:517-528.
26. Den Besten C, Bennik MH, Bruggeman I, Schielen P, Kuper F, Brouwer A, Koeman JH, et al. The role of oxidative metabolism in hexachlorobenzene-induced porphyria and thyroid hormone homeostasis: a comparison with penrachlorobenzene in a 13-week feeding study. Toxicol Appl Pharmacol 1993;119:181-194.
27. Goldstein JA, Hickman P, Jue DL. Experimental hepatic porphyria induced by polychlorinated biphenyls. Toxicol Appl Pharmacol 1974;27:437-448.
28. van Birgelen AP, DeVito MJ, Akins JM, Ross DG, Diliberto JJ, Birnbaum LS. Relative potencies of polychlorinated dibenzo-p-dioxins, dibenzofurans, and biphenyls derived from hepatic porphyrin accumulation in mice. Toxicol Appl Pharmacol 1996;138:98-109.
29. Smith AG, Francis JE, Dinsdale D, Manson MM, Cabral JR. Hepatocarcinogenicity of hexachlorobenzene in rats and the sex difference in hepatic iron status and development of porphyria. Carcinogenesis 1985;6:631-636.
30. Levy JE, Montross LK, Cohen DE, Fleming MD, Andrews NC. The C282Y mutation causing hereditary hemochromatosis does not produce a null allele. Blood 1999;94:9-11.
31. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
32. Phillips JD, Kushner JP. Measurement of uroporphyrinogen decarboxylase activity. Curr Protocol Toxicol 1999;84:1-13.
33. Bulaj ZJ, Ajioka RS, Phillips JD, LaSalle BA, Jorde LB, Griffen LM, Edwards,CQ et al. Disease-related conditions in relatives of patients with hemochromatosis. N Engl J Med 2000;343:1529-1535.